Global Liquid Biopsy market is segmented based on application type: Breast, Lung, Colorectal, Liver, Prostate, and Others
Circulating Biomarker: Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA
Product: Assay kits, Instruments, Services
Geography: North America, Europe, APAC
End User: Hospitals, Laboratories
Application Analysis: Three key applications of liquid biopsy can be a therapy selection tool for metastatic breast cancers, therapy selection for other metastatic cancers, and molecular health monitoring. With the rising incidence of metastatic cancer across the globe, the therapy selection tool for metastatic breast cancers segment is poised to hold a considerable share in the market throughout the forecast period
Biomarker Type analysis: The liquid biopsy market has been divided into circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and exosomes (Macrovesicles with Protein, RNA, DNA). There are about 8-10 liquid biopsy tests based on CTCs and ctDNA that are currently commercialized. Furthermore, over 30 tests based on all three of these biomarkers are in clinical development. Commercialization of these tests in the offing is estimated to benefit the growth of the overall market.
Regional analysis: North America accounted for the largest share of the global liquid biopsy market in 2018, followed by the Asia Pacific. In North America, the United States accounted for the largest share of the liquid biopsy market. In Europe, Germany and France are the leading markets for liquid biopsy. Asia pacific is likely to be the fastest growing market for liquid biopsy during the forecasting period. In Asia Pacific, Japan and China are the leading markets for liquid biopsy. Latin America is the fourth largest market for liquid biopsy, being followed by Middle East & Africa.
End User analysis: In 2018, Reference laboratories captured the largest share of the global liquid biopsy market. Hospital and Physician laboratories occupied the second highest share of the liquid biopsy market in 2018, being followed by Academic and Research Centers
Presently, R&D on cancer diagnosis is primarily focused toward liquid biopsy. Market players and research institutes are conducting extensive clinical trials to develop a highly sensitive liquid biopsy platform. In May 2018, Grail, a U.S.-based biotechnology company, raised US$ 1 Bn in VC funding and embarked on a 120,000-patient study for early breast cancer detection.
In January 2018, researchers at Johns Hopkins developed a test called CancerSEEK, which is a non-invasive multianalyte test that analyzes levels of eight cancer proteins and presence of cancer gene mutation in circulating DNA in the blood. The test included more than 1000 patients with nonmetastatic, stages I to III cancers of the ovary, stomach, liver, pancreas, esophagus, lungs, colorectum, and breast. Extensive research on liquid biopsy aimed at promoting early diagnosis in cancer is likely to drive the market for during the forecast period
There are around 8-10 fluid biopsy tests on the basis of CTCs and ctDNA that are as of now commercialized. Moreover, more than 30 tests in view of each of the three of these biomarkers are in clinical improvement by some major market players.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.